TTrialPathMatch Me to Trials
← Back to trials
RecruitingHeart FailureNYHA Class III Heart FailureNYHA Class II Heart Failure

NORM-HF Pivotal Study

Eligible age

18+ yrs

Accepts

All genders

Locations

14 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF patients is superior for reducing the combined endpoint of worsening HF events and cardiovascular mortality compared to standard of care treatment. Patients will be randomized in a 1:1 ratio to receive either NORM™ System and guided heart failure management (intervention group) or usual standard of care with guided heart failure management (control group).

Sponsor: Foundry Innovation & Research 1, Limited (FIRE1)

You may qualify if…

  • ✓ 1. Adults 18 years of age or older.
  • ✓ 2. Provide informed consent for participation in the clinical study and be willing and able to comply with the required assessments, treatment instructions, and clinical follow-up visits according to the specified schedule.
  • ✓ 3. Patients meeting diagnostic criteria for HF diagnosis for greater than 90 days and are on optimally tolerated medical therapy for at least 30 days, as recommended according to current AHA/ACC/HFSA or ESC HF guidelines with any intolerance or contraindications documented, regardless of ejection fraction, as evidenced by meeting either 3a, 3b OR 3c criterion below:
  • ✓ 1. NYHA functional class II with documented HF decompensation within the previous 12 months resulting in a primary HF hospitalization, HF treatment in a hospital day-care setting or unscheduled visit to a healthcare provider for administration of an intravenous diuretic to treat HF AND NT-proBNP ≥1000 pg/mL. For those patients presenting with atrial fibrillation or flutter, NT-proBNP ≥1,600 pg/mL.
  • ✓ OR
  • ✓ 2. NYHA functional class III with documented HF decompensation within the previous 12 months resulting in a primary HF hospitalization, HF treatment in a hospital day-care setting or unscheduled visit to a healthcare provider for administration of an intravenous diuretic to treat HF AND NT-proBNP ≥ 600 pg/mL. For patients presenting with atrial fibrillation or flutter, NT-pro BNP ≥900 pg/mL.
  • ✓ OR
  • ✓ 3. NYHA functional class III AND NT-proBNP ≥1000 pg/mL. For patients presenting with atrial fibrillation or flutter, NT-proBNP ≥1,600 pg/mL.

You may not qualify if…

  • ✕ 1. Presence of advanced end stage HF, suggested by but not limited to:
  • ✕ Persistent NYHA functional class IV HF (ACC/AHA/ESC).
  • ✕ Current treatment with intravenous vasopressors or inotropes.
  • ✕ Received, or are likely to receive in the next 6 months, an advanced therapy (e.g., mechanical circulatory support or cardiac transplant or previously listed for transplant).
  • ✕ Receiving end of life HF care.
  • ✕ 2. Severe right sided valvular disease or a right sided mechanical valve.
  • ✕ 3. Patients with abdominal circumference of greater than 143 cm (56 inches) at screening.
  • ✕ 4. Patients with an estimated Glomerular Filtration Rate (eGFR) \< 25 mL/min/1.73m2 or receiving ultrafiltration or chronic dialysis.

Where it's recruiting

California

Chula Vista · Sacramento

Florida

Jacksonville · Tampa

Louisiana

Baton Rouge

Missouri

Kansas City

New York

New York

North Carolina

Chapel Hill

Ohio

Cincinnati · Colombus · Toledo

Pennsylvania

Philadelphia

South Carolina

Columbia · Greenville

Source: ClinicalTrials.gov · NCT07574593 · last updated 2026-10-16

NORM-HF Pivotal Study · TrialPath